Solanezumab

Solanezumab ^?

Monoclonal antibody
Type	Whole antibody
Source	Humanized
Target	Beta amyloid
Clinical data
Legal status	Investigational
Identifiers
CAS number	955085-14-0 N
ATC code	None
UNII	5D6PWO0333 Y
KEGG	D10058 N
Chemical data
Formula	C6396H9922N1712O1996S42
Mol. mass	144.1 kDa
N (what is this?)  (verify)

Solanezumab (proposed INN) is a monoclonal antibody being investigated by Eli Lilly as a neuroprotector^[1] for patients with Alzheimer's disease.^[2][3]

It binds to the amyloid-β peptides that make up the protein plaques seen in the brains of people with the disease.

2012 results of the EXPEDITION 1 & 2 phase 3 clinical trials were only mildly encouraging.^[4][5][6] but were said to be the "first evidence that targeting the amyloid cascade can slow the progression of disease.”^[7]

References

1. ↑ International Nonproprietary Names for Pharmaceutical Substances (INN, prepublication copy), World Health Organization.
2. ↑ ClinicalTrials.gov NCT00749216 Solanezumab Safety Study in Japanese Patients With Alzheimer's Disease
3. ↑ ClinicalTrials.gov NCT00905372 Effect of LY2062430 on the Progression of Alzheimer's Disease (EXPEDITION)
4. ↑ "Lilly's Solanezumab Slows Down Alzheimer's Progression". 9 Oct 2012. 
5. ↑ Solanezumab Did it actually work
6. ↑ "Eli Lilly’s solanezumab faces grim prospects of attaining conditional FDA approval in mild Alzheimer’s". 4 Sep 2012. 
7. ↑ "ALZHEIMER'S DRUG SLOWS MEMORY LOSS BY ONE THIRD". 10 Oct 2012.